U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07356544) titled 'Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC' on Jan. 14, 2025.
Brief Summary: The HEROS study is an Italian observational multicenter prospective study aimed to investigate the current diagnostic and therapeutical approach towards HER2 mutated NSCLC in clinical practice. The enrolment will start in September 2024 until September 2025. A 12-months follow-up window will be performed.
Study Start Date: Aug. 12, 2025
Study Type: OBSERVATIONAL
Condition:
NSCLC (Advanced Non-small Cell Lung Cancer)
HER2
Recruitment Status: RECRUITING
Sponsor: Gruppo Oncologi...